murepavadin

Small moleculeexperimental

Murepavadin (POL7080) is a Pseudomonas specific peptidomimetic antibiotic. It is a synthetic cyclic beta hairpin peptidomimetic based on the cationic antimicrobial peptide protegrin I (PG-1) and the first example of an outer membrane protein-targeting antibiotic class with a novel, nonlytic mechanism of action, highly active and selective against the protein transporter LptD of Pseudomonas aeruginosa. In preclinical studies the compound was highly active on a broad panel of clinical isolates including multi-drug resistant Pseudomonas bacteria with outstanding in vivo efficacy in sepsis, lung, and thigh infection models. Intravenous murepavadin is in development for the treatment of bacterial hospital-acquired pneumonia and bacterial ventilator-associated pneumonia due to Pseudomonas aeruginosa. — Wikipedia

Clinical trial activity

9 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
4
Phase 3
2
Phase 4
0

Earliest trial started Apr 1, 2013 (NCT02110459)

Timeline

2010s

  1. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2013

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2018

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetUnclear

    unclear

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • pol7080
  • ro7033877

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03582007Phase 3Sep 30, 2018Polyphor Ltd.
NCT03409679Phase 3Mar 23, 2018Polyphor Ltd.
NCT02897869Phase 1Apr 1, 2016Polyphor Ltd.
NCT02165332Phase 1Jul 1, 2014Roche
NCT02156323Phase 1Jul 1, 2014Roche
NCT02165293Phase 1Jun 1, 2014Roche
NCT02096315Phase 2Dec 1, 2013Polyphor Ltd., University of Barcelona, University of Edinburgh
NCT02096328Phase 2Oct 1, 2013Polyphor Ltd., University of Athens, University of Barcelona
NCT02110459Phase 1Apr 1, 2013CRS Clinical Research Services Kiel GmbH, Polyphor Ltd.
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Polyphor Ltd.For profit6632013
RocheFor profit3312014
University of BarcelonaAcademic/Hospital2012013
CRS Clinical Research Services Kiel GmbHFor profit1012013
University of AthensAcademic/Hospital1012013
University of EdinburghAcademic/Hospital1012013
6 organizations
Page 1 / 1